Oro Valley, AZ (PRWEB) August 27, 2013
Convoy Therapeutics, Inc. has been selected to present at the 2013 Rocky Mountain Life Science Investor and Partnering Conference. The conference will take place on September 18-19, 2013 in Denver, Colorado and is hosted by the Colorado BioScience Association. Convoy Therapeutics is one company among a field of just thirty from Colorado, Arizona, Utah, Montana, and New Mexico that was chosen to present.
Convoy Therapeutics is a subsidiary of ACTUS Biotechnologies, Inc., an accelerator focused on development of novel technologies into commercially available therapies. The Convoy Therapeutics platform technology is based upon a family of peptides, including the proprietary "SPACE" (Skin Penetrating and Cell Entering) peptide. Studies using the peptide in topical formulations with and without covalent attachment have demonstrated an exceptional ability to deliver molecules as large as 1.6 megadaltons past the stratum corneum and into the deeper layers of the skin. Additionally, the technology is capable of creating reservoirs of small molecules, enhancing retention and decreasing dosing frequency, and a demonstrated ability to enhance the penetration of nucleic acids into the skin and cells.
The Convoy Therapeutics platform technology has an enormous range of potential applications in the pharmaceutical, medical aesthetic, cosmetic and vaccine industries, including the opportunity to transform current oral and intravenous drugs into topical formulations for the treatment of dermatological and other diseases.
The company’s lead programs include a topical cosmetic Hyaluronic Acid product for the reduction of fine lines and wrinkles for use between filler or toxin injections, and CycloPsorb™, a topical cyclosporine prescription product for the treatment of psoriasis. The platform is also being investigated with a number of pharmaceutical and cosmetic partners for use with a variety of large and small molecules. Given the challenge that topical macromolecule delivery has posed to the pharmaceutical industry for so many years, the results of the Convoy Therapeutics platform have been remarkable.
For more information on Convoy Therapeutics, visit the company’s website here. For information on ACTUS Biotechnologies, visit the company’s website here. Additional information on the Rocky Mountain Life Science Investor and Partnering Conference can be found here.